Friday, 19 Jan 2018

You are here

lxekizumab Performance in TNF Nonresponders Phase 3 Trial

Ixekizumab performs well in TNF nonresponders phase 3 trial.

With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies the question of efficacy and safety in different clinical scenarios arises.

The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.

Acr 20 was assessed in 24 weeks as a primary end point. 16 week escape was allowed.

 

 

Best response was observed in arthritis and dactylitis domain in both IXE groups with ACR20 65 [53.3%], 59 [48%] vs. 23 [19.5%]; Q4W, Q2W, placebo, respectively. At the same, rates of enthesitis resolution were not significantly different compared to placebo. 

 

In terms of safety, serious AE and oral candidiasis were numerically higher with Q2W vs placebo. No deaths or cases of inflammatory bowel disease, uveitis, TB reactivation, or grade ≥3 neutropenia were reported.

The study concluded that IXE improves arthritis, skin psoriasis and physical function with no unexpected safety findings in patients with active PsA and prior IR or intolerance to TNF-inhibitor(s).

The safety profile of IXE was comparable to safety findings from SPIRIT-P1 trial.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 19 January 2018

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the rising cost of adalimumab, infections in myositis, phyisician burnout, biologics in Still's disease and weight loss benefits in RA. 

Rheumatology Physician Burnout and Depression

The 2018 Medscape Physician Burnout and Depression report shows that 42% of physician respondents report "burnout" and up to 15% experience some sort of depression. In a survey of 15,543 doctors from 29 specialties, they found highest burnout rates in critical care and neurologists (48%), family medicine (47%), ob/gyns and internists (46%). Lowest rates were seen in pathology and dermatology (32%), and plastic surgery (23%). 

What did rheumatologists report?

The RheumNow Week in Review - 12 January 2018

Dr. Jack Cush reviews a dozen highlights from the past week on RheumNow.com.

40% of Arthritis Patients Fail to Receive Exercise Guidance

The latest issue of CDC’s MMWR reports that exercise counseling among arthritis patients increased from 52% to 61% (2002 to 2014); hence ~40% do not receive health care provider counseling, suggesting the need for provider education and training in exercise counseling, and improved electronic medical record reminders.

The RheumNow Week in Review - 5 January 2018

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.